Related by context. All words. (Click for frequent words.) 69 choroidal neovascularization 66 choroidal neovascularisation 66 Central Retinal Vein 64 macular edema secondary 64 Intravitreal 64 central retinal vein 64 occlusion CRVO 64 choroidal neovascularization CNV 63 geographic atrophy 63 progressive MS SPMS 63 EVIZON ™ 63 retinal vein occlusion induced 63 Anti VEGF 63 pathologic myopia 63 neovascular 62 Squalamine 61 denileukin diftitox 61 chronic thromboembolic pulmonary 61 choroidal vasculopathy 61 EVIZON TM 61 acetonide FA 61 pegaptanib 61 Ranibizumab 60 Geographic Atrophy 60 neovascular age 60 induced macular edema 60 glaucoma diabetic retinopathy 60 Neovascular AMD 60 intravitreal bevacizumab 60 vasculopathy 60 thalidomide Thalomid 60 ocular disorders 60 myoglobinuria 60 Neovascularization 60 diabetic retinopathy DR 60 iSONEP TM 60 glaucoma cataracts 59 predominantly classic subfoveal 59 retinal vein occlusion RVO 59 acute peripheral arterial 59 arterial thrombosis 59 neovascular form 59 Bevasiranib 59 PresbyLens ® 59 kidney urologic 59 secondary hyperparathyroidism 59 neovascular wet age 59 presumed ocular histoplasmosis 59 Refractory Hodgkin Lymphoma 59 CYT# potent vascular disrupting 59 antiangiogenic agent 59 ocular angiogenesis 59 squalamine 59 retinal vein occlusion 59 unresectable tumors 58 exudative 58 myelodysplastic myeloproliferative diseases 58 hyperoxaluria 58 neovascular diseases 58 Investigational Treatment 58 Intravitreal injections 58 malignant ascites 58 Myelodysplastic Syndrome MDS 58 Dupuytren Disease 58 valvular heart disease 58 humanized therapeutic 58 iSONEP ™ 58 Lucentis ranibizumab 58 Aflibercept 58 oropharyngeal candidiasis OPC 58 Deforolimus 58 Naive Patients 58 Angiotensin Converting Enzyme 58 Angioedema 58 catheter occlusion 58 AA Amyloidosis 58 dilated cardiomyopathy DCM 58 Vitrasert R 58 HeFH 58 targeted radiotherapeutic 58 Neovascular Age Related Macular 58 Initiates Phase II 58 treat chronic sinusitis 58 receptor tyrosine kinase inhibitor 58 Aurora Kinase 58 patientswith 58 INS# [001] 58 Atypical Hemolytic Uremic Syndrome 58 Stargardt Macular Dystrophy 58 diabetic gastroparesis 58 invasive candidiasis 57 R lenalidomide 57 Orally administered 57 humanised monoclonal antibody 57 metastatic malignant 57 psoriasis vulgaris 57 immunomodulatory therapy 57 inhibit platelet function 57 MGd 57 pulmonary hypertension PH 57 mycophenolic acid 57 oral anti arrhythmic 57 Raynaud disease 57 Diabetic Retinopathy 57 neovascular AMD 57 Achieves Primary Endpoint 57 Non Alcoholic Steatohepatitis 57 hyperparathyroidism 57 atherosclerosis plaque buildup 57 Hedgehog Pathway Inhibitor 57 generalized seizures 57 relapsed MM 57 proliferative retinopathy 57 delivers fluocinolone acetonide FA 57 phase IIb clinical 57 topically administered 57 macular degeneration diabetic retinopathy 57 atypical hemolytic uremic syndrome 57 polycythemia vera essential thrombocythemia 57 Vidaza azacitidine 57 lexidronam injection 57 anti angiogenic agent 57 Teriflunomide 57 prematurity ROP 57 diabetic macular edema 57 either acutely decompensated 57 prokinetic agent 57 MTP inhibitor 57 hypereosinophilic syndrome 57 anti angiogenic agents 57 headache nasopharyngitis 57 deCODE Glaucoma TM 57 esophageal candidiasis 57 geographic atrophy GA 57 psoriatic arthritis PsA 57 lung fibrosis 57 ® lenalidomide 57 optic neuropathy 56 sitaxsentan 56 haematologic 56 photodynamic therapy PDT 56 Gets FDA Clearance 56 anterior uveitis 56 primary immunodeficiency PI 56 posterior uveitis 56 sorafenib Nexavar 56 metastatic colorectal 56 Microplasmin 56 ranibizumab Lucentis 56 trial evaluating PRX# 56 basiliximab 56 Ribavirin causes 56 cutaneous lupus 56 Aortic stenosis 56 Vidaza ® 56 ocular inflammatory 56 Diabetic Macular Edema 56 Sjogren syndrome 56 Raynaud phenomenon 56 Letairis ambrisentan 56 Perceiva 56 Biolimus A9 56 Fuchs dystrophy 56 brivanib 56 SPRYCEL ® 56 intranasal formulation 56 PEGylated Fab fragment 56 Gemzar gemcitabine 56 orally inhaled migraine 56 Completes Patient Enrollment 56 Initiates Clinical Trial 56 CRVO 56 ergot derivatives 56 bullous 56 CYT# QbG# 56 Diabetic Retinopathy DR 56 transthyretin amyloidosis 56 Vascular Disrupting Agent 56 novel oral anticoagulant 56 targeted nucleotide prodrug 56 vapreotide acetate 56 familial hypercholesterolemia FH 56 alkylating agent 56 PNP inhibitor 56 glaucoma macular degeneration 56 bortezomib Velcade 56 Cytarabine 56 selective phosphodiesterase 56 severe malignant osteopetrosis 56 Dasatinib 56 advanced medullary thyroid 56 vWD 56 benign prostatic hypertrophy BPH 56 R sorafenib tablets 56 Shows Promise Against 56 dyslipidemia hypertension diabetes 56 interferon alpha IFN 56 FUSILEV enhances 56 Ophena TM 56 generation purine nucleoside 56 PAOD 56 small molecule tyrosine 56 EVIZON 56 arterial calcification 55 C. pneumoniae 55 Iluvien TM 55 superficial basal cell carcinoma 55 PEG uricase 55 Acute Exacerbations 55 pan histone deacetylase 55 Aliskiren 55 pediatric Crohn disease 55 de novo AML 55 myopic macular degeneration 55 essential thrombocythemia ET 55 Diabetic Macular Edema DME 55 Kamada AAT 55 GW# [003] 55 hypercholesterolaemia 55 AVAPRO 55 Degeneration AMD 55 macular edema 55 PTK# 55 hyperphenylalaninemia HPA due 55 Meets Primary Endpoint 55 lichen planus 55 Initiates Enrollment 55 carnitine deficiency 55 RTP #i 55 diabetic retinopathy glaucoma 55 Phase 2b Clinical Trial 55 PPAR gamma agonist 55 FOLFOX6 chemotherapy regimen 55 5 fluorouracil leucovorin 55 factor VIIa 55 endometrial hyperplasia 55 retinal degenerations 55 laser photocoagulation 55 M# rationally 55 diabetic kidney 55 alpha1 antitrypsin deficiency 55 mycosis fungoides 55 Initiates Phase III 55 toenail onychomycosis 55 Wet AMD 55 Benign Prostatic Hyperplasia BPH 55 GERD migraine headaches 55 symptomatic benign prostatic 55 erlotinib Tarceva ® 55 PEGylated interferon 55 novel emulsion formulation 55 IAP inhibitor 55 sunitinib Sutent 55 Interferon beta 55 Temodar temozolomide 55 eosinophilic asthma 55 Xelox 55 Diabetic nephropathy 55 reversible inhibitor 55 lysosomal storage disorder 55 autoimmune uveitis 55 idiopathic thrombocytopenic purpura ITP 55 Silodosin 55 Barrett esophagus BE 55 Mg Uk 55 systemic juvenile idiopathic 55 parathyroid carcinoma 55 neuronal nicotinic receptor NNR 55 papillary renal cell carcinoma 55 homozygous familial hypercholesterolemia 55 Factor VIIa 55 Patients Treated With 55 metastatic gastric 55 Kinase Inhibitor 55 Zybrestat 55 Cand5 54 Panzem ® 54 systemic amyloidosis 54 osteosarcomas 54 mixed hyperlipidemia 54 metaglidasen 54 corticosteroid dexamethasone 54 rhIGF-I/rhIGFBP-3 54 ZOLINZA 54 non resectable 54 Temsirolimus 54 gefitinib Iressa 54 Cloretazine 54 prescribed proton pump 54 Fibrillex TM 54 Pivotal Phase III 54 diarrhea predominant irritable 54 Prednisone Against Refractory 54 PEG IFN 54 thyroid deficiency 54 giant cell arteritis 54 AGGRASTAT R Injection tirofiban 54 optic neuropathy NAION 54 lintuzumab SGN 54 vinca alkaloid 54 TNF Tumor Necrosis Factor 54 Carbaglu 54 TLK# 54 LAB CGRP 54 Temodar ® 54 cisplatin gemcitabine 54 neoadjuvant setting 54 oral prodrug 54 glaucoma cataract 54 anemias 54 vulvovaginal atrophy 54 SYN# 54 Initiate Clinical Trial 54 antimetabolite 54 pancreatic insufficiency 54 purpura 54 Pegloticase 54 Investigational Oral 54 midstage clinical 54 Benign Prostatic Hyperplasia 54 Pafuramidine 54 non resectable metastatic 54 Bucindolol 54 CTAP# 54 ischemic optic neuropathy 54 cromolyn sodium 54 Begins Dosing 54 Plaquenil 54 Macular edema 54 cough dyspnea 54 basal cell carcinoma BCC 54 Phase #b/#a clinical 54 OHR/AVR# 54 HepDirect prodrug 54 lymphomas leukemias 54 atherothrombotic events 54 exocrine pancreatic insufficiency EPI 54 wet macular degeneration 54 AMD diabetic retinopathy 54 engineered anticoagulant 54 volociximab 54 2A receptor agonist 54 peripherally acting 54 multifactorial disease 54 sargramostim 54 dystrophies 54 multitargeted 54 Lixivaptan 54 ocular hypertension 54 related Macular Degeneration 54 RELOVAIR ™ 54 diabetic macular edema DME 54 elevated IOP 54 erythematosus 54 histone deacetylase HDAC inhibitor 54 Novel Oral 54 MELAS 54 CYP#A# CYP#D# 54 vitreous hemorrhage 54 MAGE A3 ASCI 54 Bevacizumab Avastin 54 Darapladib 54 hoFH 54 INSPIRE Trial Phase III 54 BRAF inhibitor 54 Completes Enrollment 54 lung pancreatic 54 mitoxantrone plus 54 intravenous recombinant 54 Juvenile Idiopathic Arthritis 54 Neovascular 54 2 methoxyestradiol 54 NASH Huntington 54 Hepatocellular Carcinoma HCC 54 Presents Preclinical Data 54 including eniluracil ADH 54 Adenoscan R 54 etanercept Enbrel 54 cutaneous squamous cell carcinoma 54 INCB# [003] 53 bladder ovarian 53 Kuvan sapropterin dihydrochloride 53 gets USFDA nod 53 refractory angina 53 Hsp# Inhibitor 53 dasatinib Sprycel ® 53 tamoxifen citrate 53 hormone refractory metastatic prostate 53 ALTROPANE R 53 p# MAP kinase inhibitor 53 topically applied SEPA 53 multiple myeloma MM 53 VA# [002] 53 hyaluronidase enzyme 53 overt nephropathy 53 nephropathic cystinosis 53 targeted antifolate 53 induced anemia 53 myelofibrosis polycythemia vera 53 MetroGel 53 treatmentof 53 Omacetaxine 53 benign prostatic hypertrophy 53 Bayer HealthCare Onyx Pharmaceuticals 53 Safinamide 53 presymptomatic 53 sorafenib tablets 53 docetaxel Taxotere ® 53 hematologic disorders 53 induced mucositis 53 Factor Xa inhibitor 53 demonstrated antitumor activity 53 oral beclomethasone dipropionate 53 EVIZON TM squalamine lactate 53 reslizumab 53 neuropathic pain spasticity 53 pain palliation 53 Shows Statistically Significant 53 INxin 53 PsA 53 Presents Preclinical 53 aurora kinase 53 juvenile idiopathic arthritis 53 Sjogren Syndrome 53 oral nucleoside analogue 53 liver scarring 53 COPEGUS R 53 Bezielle 53 Almorexant 53 Acne vulgaris 53 myelofibrosis MF 53 Age Related Macular 53 TG# [003] 53 Submits IND 53 cataracts glaucoma 53 leukemia AML 53 OSI Tarceva 53 fibromyalgia syndrome 53 BrachySil ™ 53 elevated intraocular pressure 53 plasma kallikrein 53 diabetes mellitus DM 53 strabismus crossed 53 AFREZZA TM 53 Retinopathy 53 CIMZIA r certolizumab pegol 53 ADPKD 53 Stargardt Macular Dystrophy SMD 53 Technosphere ® 53 Pyridorin 53 ASONEP ™ 53 5 FU leucovorin 53 idiopathic pulmonary fibrosis IPF 53 cell carcinoma RCC 53 AREDS 53 DURIN TM 53 Etanercept 53 LHON 53 Fenretinide 53 Antiangiogenic 53 ACAPODENE TM 53 Xyfid TM 53 EGFR mutation positive 53 p# inhibitor 53 molecular imaging radiopharmaceutical 53 onset seizures 53 Xanafide 53 novel histone deacetylase 53 PDX pralatrexate 53 reflux disease 53 tacrine 53 R Saizen R 53 Factor Receptor 53 macular disease 53 motor neuron degeneration 53 Drug Candidate 53 novel VDA molecule 53 nilotinib Tasigna ® 53 hypoxia activated prodrug 53 bevasiranib 53 atypical Hemolytic Uremic Syndrome 53 Adenoviral 53 Receives Orphan Drug Designation 53 cortisol synthesis 53 familial amyloidotic polyneuropathy FAP 53 TTR amyloidosis 53 non porcine pancreatic 53 Darusentan 53 neovascularization 53 Glatiramer acetate 53 refractory chronic lymphocytic 53 non thiazolidinedione TZD 53 Romidepsin 53 OvaRex R 52 Akt inhibitor 52 hematological malignancy 52 macular 52 JAK2 Inhibitor 52 Glypromate 52 Maribavir 52 candidate TNFerade biologic 52 relapsing remitting 52 oxypurinol 52 cardiotoxic 52 brand ciclesonide HFA 52 open angle glaucoma 52 PI3K/Akt pathway inhibitor 52 Files IND 52 proliferator activated receptor 52 uvea 52 Sjögren syndrome 52 Cancer Cachexia 52 Rindopepimut 52 PF # [002] 52 Initiates Clinical 52 aldehyde dehydrogenase ALDH2 deficiency 52 Prodarsan R 52 radiation enteritis 52 opioid induced constipation OIC 52 lamotrigine Lamictal 52 NeuroSTAT ® 52 Mipomersen 52 amblyopia lazy eye 52 non arteritic anterior ischemic 52 Sezary syndrome 52 Initiate Phase 52 Panzem R 52 Bazedoxifene 52 retinal pigment epithelial 52 orally administered inhibitor 52 metastatic carcinoid 52 Ankylosing spondylitis 52 orally disintegrating 52 Critical Limb Ischemia 52 DEB# 52 basal cell nevus syndrome 52 acne vulgaris 52 Nexavar tablets 52 MKC# MKC# PP 52 3 registrational trial 52 candidates Azedra TM 52 Alzheimer Disease AD 52 AKT inhibitor 52 Transdermal Patch 52 Annamycin 52 SNT MC# 52 thetreatment 52 FDA Okays 52 prematurity Stargardt disease 52 efalizumab 52 SinuNase TM 52 onset diabetes mellitus 52 proteasome inhibitor 52 selective androgen receptor modulator 52 Immunotherapeutic 52 PrevOnco 52 TELINTRA R 52 Severe Primary IGFD 52 TELINTRA 52 gastrointestinal stromal tumor 52 smoldering myeloma 52 pioglitazone hydrochloride 52 vidofludimus 52 retinal disorders 52 acyclovir Lauriad R 52 inhalation powder 52 Alemtuzumab 52 ropinirole Requip 52 Donepezil 52 CMV retinitis 52 exploratory endpoints 52 donepezil Aricept 52 hereditary emphysema 52 Cotara ® 52 Eculizumab 52 anti angiogenic therapy 52 Posaconazole 52 glioblastoma multiforme GBM 52 viral conjunctivitis 52 commercialize deforolimus 52 OMNARIS HFA 52 LymphoStat B TM 52 lenalidomide Revlimid R 52 abdominal abscesses 52 BCR ABL mutations 52 Panzem R NCD 52 Muraglitazar 52 Vascular dementia 52 Amgen Neulasta R 52 MKC# MT 52 KRN# 52 cataract glaucoma 52 topical gel formulation 52 docetaxel Taxotere R 52 vinorelbine tartrate 52 Licenses Novel 52 antimitotic 52 nonalcoholic steatohepatitis NASH 52 Leber congenital amaurosis LCA 52 OvaRex ® MAb 52 Vaprisol 52 vascular disrupting agents 52 Sudhir Agrawal D.Phil 52 aortic valve stenosis 52 XP# XP# 52 topical gel containing 52 diarrhea fatigue asthenia 52 TRIOLEX HE# APOPTONE HE# 52 Shigatoxin producing E. coli 52 systemically administered 51 Sphingomab TM 51 Spiegelmer ® 51 hematological diseases 51 dasatinib Sprycel 51 Generx TM 51 retinal dystrophies 51 Ocular Hypertension 51 phase IIb III 51 Squamous cell 51 alpha1 antitrypsin AAT deficiency 51 Xerostomia 51 refractory colorectal cancer 51 Apoptone HE# 51 Initiates Phase 2b 51 amnestic mild cognitive impairment 51 sirtuin inhibitor program 51 liposomal formulation 51 huC# DM4 51 Tykerb lapatinib 51 nonalcoholic steatohepatitis 51 subependymal giant cell 51 dual orexin receptor 51 TOCOSOL 51 Phase 2a Clinical Trial 51 epithelial tumors 51 Submits NDA 51 DCVax R 51 Unit Dose Budesonide 51 PRN FDA Approves 51 Peyronie Disease 51 inherited retinal degeneration 51 Ostabolin C TM 51 erlotinib Tarceva 51 cartilage degeneration 51 THR beta agonist 51 rheumatoid arthritis inflammatory bowel 51 Allegra Oral Suspension 51 Peginterferon alfa 2b 51 chronic periodontitis 51 lomitapide 51 BRAF mutant 51 Peripheral arterial disease 51 Retaane 51 fenretinide 51 Aclidinium 51 AERx ® 51 Iluvien ® 51 delta gamma agonist 51 Leber Congenital Amaurosis LCA 51 metastatic pancreatic 51 BCG refractory carcinoma 51 Lennox Gastaut syndrome 51 JAK2 inhibitor 51 Personalized Immunotherapy 51 Combivir Kivexa 51 Bob Butchofsky President 51 Bosutinib 51 DFMO 51 psoriasis rheumatoid arthritis 51 Peripheral artery disease 51 refractory gout 51 Optiquel ™ 51 Familial Adenomatous Polyposis FAP 51 undergoing hematopoietic stem 51 active ankylosing spondylitis 51 inhibitor COX 51 ruboxistaurin 51 ASONEP TM 51 PDE# inhibitors 51 candidate deforolimus 51 Retinitis Pigmentosa RP 51 histone deacetylase inhibitor 51 myeloproliferative disorders 51 Liprotamase 51 lupus erythematosus 51 Parkinson Disease PD 51 Pulmonary hypertension 51 dihydrochloride 51 Salagen 51 xerostomia 51 dyskeratosis congenita 51 Zemiva ™ 51 diabetic peripheral neuropathy 51 G6PD deficiency 51 Cinquil 51 fibrotic disease 51 vaginal candidiasis 51 Leukine ® 51 Phase IIb clinical trials 51 cetuximab Erbitux R 51 5 HT2A inverse 51 delivery polymer matrix 51 chemosensitizer 51 TBC# 51 PrevOnco ™ 51 selective estrogen receptor modulator 51 overactive bladder AA# 51 systemic fungal infections 51 purpura ITP 51 Behcet uveitis 51 chemotherapy induced neutropenia 51 Vertex hepatitis C 51 myopia nearsightedness 51 efaproxiral 51 postoperative ileus 51 infectious diseases autoimmune diseases 51 syndrome gastroesophageal reflux 51 Rilonacept 51 Zemiva TM 51 Avanafil 51 jaundice yellowing 51 rifalazil 51 Neurodegenerative diseases 51 beta 1a 51 Trofex 51 Doxil ® 51 nerve degeneration 51 macular degeneration glaucoma 51 neuropathic pain metabolic diseases 51 radiation sensitizer 51 itraconazole Sporanox 51 CMV vaccine 51 Solazed 51 Acute Myelogenous Leukemia AML 51 NS5B polymerase 51 LEP ETU 51 anti PlGF 51 macroalbuminuria 51 Daclizumab 51 POAG 51 PDE4 inhibitor 51 non nucleoside inhibitor 51 indolent follicular non 51 Cancidas 51 liver fibrosis 51 OMP #M# 51 malignant pleural mesothelioma 51 Cholangiocarcinoma 51 diabetic retinopathy macular degeneration 51 tolevamer 51 Leber Hereditary Optic Neuropathy 51 castrate resistant prostate cancer 51 alemtuzumab Campath 51 drug NP2 Enkephalin 50 skeletal sarcomere activator 50 Augment ™ 50 IL# PE#QQR 50 Pathway Inhibitor 50 ALN PCS 50 JAK inhibitor 50 FSAD 50 KSP inhibitor 50 constipation predominant irritable bowel 50 antihormonal 50 Collategene 50 overactive bladder OAB 50 retinitis pigmentosa RP 50 Troxatyl 50 TOCOSOL Camptothecin 50 osteoarthritis rheumatoid arthritis 50 NU# direct 50 neuro inflammatory 50 protein misfolding diseases 50 chimeric monoclonal antibody 50 cannabinor 50 systemic anaplastic large 50 VEGFR2 inhibitor 50 atherosclerotic disease 50 Genentech Rituxan 50 VEGF inhibitor 50 gastro intestinal inflammation 50 Reports Preclinical Data 50 ATL# [002] 50 Keratitis 50 gastrointestinal stromal 50 5 HT2A serotonin 50 investigational therapies 50 evaporative dry 50 IMiDs ® 50 multiple sclerosis lupus 50 bucindolol hydrochloride 50 knee osteoarthritis OA 50 Oral NKTR 50 proliferative diabetic retinopathy 50 antisense inhibitors 50 Retisert ® 50 TKB# 50 investigational integrase inhibitor 50 omacetaxine mepesuccinate 50 GEM OS2 50 myeloproliferative diseases 50 D aspartate NMDA receptor 50 topical antifungal 50 seborrheic dermatitis 50 iobenguane 50 Panzem NCD 50 Serostim ® 50 Idiopathic pulmonary fibrosis IPF 50 T2DM 50 potent suppressor 50 myelodysplastic syndrome MDS 50 MKC# 50 Noxafil 50 Fabry Disease 50 ARC# [002] 50 hypophosphatasia 50 Solazed TM 50 triggers apoptosis programmed 50 ATRA IV 50 Cachexia 50 primary generalized tonic 50 ion mass spectrometer 50 xerostomia secondary 50 proprietary intravenous formulation 50 schizophrenia CIAS 50 inflammatory autoimmune diseases 50 lumiliximab 50 NB S# strontium malonate 50 investigational hepatitis C 50 IMA# 50 pan HDAC inhibitor 50 Ozurdex 50 inflammatory acne 50 atrophic 50 small molecule Hedgehog 50 lupus renal disease 50 cystic fibrosis allergic rhinitis 50 Elagolix 50 FOLOTYN ® 50 inhaled liposomal ciprofloxacin 50 Nexavar sorafenib 50 accumulate preferentially 50 transthyretin 50 ALN TTR# 50 Dose Escalation Study 50 Omalizumab 50 intermittent claudication 50 common neurovascular complication 50 TLR8 agonist 50 T1DM 50 SHPT 50 ALK inhibitor 50 non constipating irritable 50 highly selective inhibitor 50 denufosol tetrasodium 50 Barrett Esophagus 50 Zorbtive TM 50 non hodgkin lymphoma 50 Oral Spray 50 Bayer Onyx 50 lumbar spinal stenosis LSS 50 Fibrillex 50 juvenile myoclonic epilepsy 50 HQK 50 optic atrophy 50 Evoltra ® 50 MACUGEN 50 mixed dyslipidemia 50 Crofelemer budesonide foam 50 Xcytrin R 50 metastatic renal cell carcinoma 50 INTEGRILIN ® 50 Opterone R 50 ALVESCO ® 50 Vitamin B# deficiency 50 Aviptadil 50 SILENOR TM doxepin HCl 50 Synovial sarcoma 50 monoclonal antibody conjugated 50 elevated triglyceride levels 50 AAG geldanamycin analog 50 Friedreich Ataxia FRDA 50 HSP# inhibitor 50 rheumatoid arthritis psoriatic arthritis 50 Mitral regurgitation 50 Laquinimod 50 octreotide implant 50 symptomatic BPH 50 gastro intestinal disorders 50 Interferon Beta 50 novel therapeutic antibodies 50 compound AEZS 50 faropenem medoxomil 50 congenital blindness 50 Nektar proprietary 50 Zoraxel 50 nondemented 50 diabetic microvascular complications 49 Associated Adipose Redistribution 49 hyperammonemia 49 hypoparathyroidism 49 aerosolized AAT 49 cirrhosis liver failure 49 IV Busulfex 49 fludarabine phosphate 49 modified glutathione analog 49 treat hyperphosphatemia 49 Simulect 49 therapeutic monoclonal antibody 49 ATTR PN 49 Hurler syndrome 49 RhuDex ® 49 iritis 49 chronic immune thrombocytopenic 49 GVAX ® 49 Soriatane 49 Actimmune ® 49 investigational pharmacologically unique 49 novel immunotherapies 49 ecabet sodium 49 ATTR 49 solanezumab 49 Kuvan R 49 iSONEP 49 mertansine 49 refractive error 49 NS#/#A protease 49 Submits Response 49 EGS# 49 Xeloda ® 49 degenerative retinal diseases 49 Olaparib 49 dornase alfa 49 retinal detachment 49 progressive metastatic prostate 49 refractory metastatic 49 related maculopathy 49 IMiDs R 49 Amgen denosumab 49 degenerative neurological diseases 49 degenerative retinal disease 49 Beta thalassemia 49 DepoCyt 49 anti VEGF 49 TAXUS Element Paclitaxel Eluting 49 treat secondary hyperparathyroidism 49 radiotherapeutic 49 ® bortezomib 49 ONCONASE R 49 candidate Zemiva TM 49 uveal melanoma 49 RhuDex R 49 Initiates Dosing 49 AA amyloidosis 49 neurodegenerative disorder characterized 49 psoriasis Crohn disease 49 Diabetic neuropathy 49 infantile spasms IS 49 Aganocide 49 apomorphine hydrochloride 49 Fx #A 49 venous blood clots 49 anti infective treatments 49 gastrointestinal disorders characterized 49 Myolimus 49 virus HCV protease inhibitor 49 severe ocular allergies 49 Pimavanserin 49 use transdermal sumatriptan 49 Granted Orphan Drug 49 Aceon 49 Eye Disease 49 CB2 selective receptor agonist 49 pemphigus 49 Solzira ™ 49 superparamagnetic iron oxide nanoparticles 49 Dr. Isaac Lipshitz 49 Iron deficiency anemia 49 mild vasodilator 49 RNAi therapeutic targeting 49 pralatrexate injection folate analogue 49 gastrin analogue TT 49 anionic backbone 49 Primary IGFD 49 Amgen Neulasta ® 49 clonic seizures 49 shingles herpes zoster 49 Aricept donepezil 49 midstage clinical trials 49 ranibizumab 49 injectable investigational 49 pathway inhibitor 49 IMPDH inhibitor 49 inhaled antibiotic 49 rusalatide acetate 49 Lennox Gastaut Syndrome 49 initiated Phase Ib 49 heterozygous familial hypercholesterolemia 49 Medulloblastoma